Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000679387 | SCV000806278 | likely benign | not provided | 2017-10-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002066990 | SCV002421522 | likely benign | Neurofibromatosis, type 1 | 2025-01-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002066990 | SCV002560697 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002499196 | SCV002805200 | likely benign | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2021-08-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004559342 | SCV005048388 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2015-07-24 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV000679387 | SCV005212427 | likely benign | not provided | criteria provided, single submitter | not provided |